glp-1 drugs and parkinson's disease drug shows little benefit for people with | UCL News glp 1 parkinson's disease GLP-1

A 2024 study published in JAMA Ophthalmology reported that patients with Type 2 diabetes who took semaglutide-containing medications had more than a fourfold higher risk for developing non-arteritic anterior ischemic optic neuropathy (NAION) compared with patients not on a GLP-1 agonist

In certain situations, a combination of Western and Eastern methods may yield the best results

have previously reported that AGEs can inactivate the complement regulatory protein CD59 (protectin) and hence increase the deposition of membrane attack complex (MAC) in tissues and vascular walls of diabetic patients (134)

Pharmaceuticals (2024) 17:497

The experiment comprised two factors (drought level and genotype) in a factorial fashion in a randomized complete block design (RCBD) with four replications